These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Atorvastatin: its clinical role in cerebrovascular prevention. Gaspardone A; Arca M Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521 [TBL] [Abstract][Full Text] [Related]
3. What does the future hold for diabetic dyslipidaemia? Crespin SR Acta Diabetol; 2001; 38 Suppl 1():S21-6. PubMed ID: 11829450 [TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
8. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors. Lopez LM Am J Health Syst Pharm; 2002 Jun; 59(12):1173-9; quiz 1180-2. PubMed ID: 12073858 [TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147 [TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Wiviott SD; Cannon CP Curr Opin Lipidol; 2006 Dec; 17(6):626-30. PubMed ID: 17095906 [TBL] [Abstract][Full Text] [Related]
11. Statins and stroke prevention. Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685 [TBL] [Abstract][Full Text] [Related]
12. Interventions in the management of serum lipids for preventing stroke recurrence. Manktelow B; Gillies C; Potter JF Cochrane Database Syst Rev; 2002; (3):CD002091. PubMed ID: 12137644 [TBL] [Abstract][Full Text] [Related]
13. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Collins R; Armitage J; Parish S; Sleight P; Peto R; Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485 [TBL] [Abstract][Full Text] [Related]
14. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Bangalore S; Fayyad R; Kastelein JJ; Laskey R; Amarenco P; DeMicco DA; Waters DD Am J Med; 2016 Apr; 129(4):384-91. PubMed ID: 26551986 [TBL] [Abstract][Full Text] [Related]
15. Pharmacologic therapy of lipid disorders in the elderly. Aronow WS Am J Geriatr Cardiol; 2002; 11(4):247-56. PubMed ID: 12091773 [TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Pedersen TR Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729 [TBL] [Abstract][Full Text] [Related]
18. Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol. van Dam M; van Wissen S; Kastelein JJ J Cardiovasc Risk; 2002 Apr; 9(2):89-95. PubMed ID: 12006916 [TBL] [Abstract][Full Text] [Related]
19. Statins in stroke prevention: what an internist should know. Castilla Guerra L; del Carmen Fernández Moreno M; López Chozas JM; Jiménez Hernández MD Eur J Intern Med; 2008 Jan; 19(1):8-14. PubMed ID: 18206595 [TBL] [Abstract][Full Text] [Related]
20. [Statins in the secondary prevention of stroke: New evidence from the SPARCL Study]. Castilla-Guerra L; Fernández-Moreno Mdel C; López-Chozas JM Clin Investig Arterioscler; 2016; 28(4):202-8. PubMed ID: 26150172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]